Our Endpoints 100 survey captured the bleakest biotech outlook we've seen in a decade. But with signs of deal flow and new FDA signals emerging, the question now is: Are executives seeing a real recovery ahead, or just another false start?
Join Editor-in-Chief John Carroll as he breaks down our latest survey results and uncovers what the data reveal about where the industry stands as 2025 winds down.
This is your chance to hear unfiltered takes on whether the fundamentals are finally shifting or if the sector's challenges are far from over. The data are drawn from a survey of select biopharma CEOs and industry experts. Register now to join the conversation.
